Table 3.
Comparison of the physicochemical characteristics of nanoparticles in aqueous suspensions and lyophilized formulations with and without PEG.
| PEG (150 mg) 1 | PSD (nm) 2 | PdI | ZP (mV) | PSD (nm) | PdI | ZP (mV) |
|---|---|---|---|---|---|---|
| Suspended SLNs | Lyophilized SLNs | |||||
| Brij S100 | 190.9 | 0.096 | 25.1 | 315.1 | 0.199 | 28.0 |
| DSPE | 171.5 | 0.131 | 27.5 | 234.6 | 0.190 | 36.9 |
| Gelucire | 171.2 | 0.155 | 27.4 | 211.1 | 0.225 | 32.6 |
| Myrj 52 | 183.1 | 0.187 | 31.4 | 280 | 0.256 | 31.6 |
| Myrj S100 | 180.1 | 0.138 | 27.4 | 235.9 | 0.180 | 29.5 |
| CO | 202.1 | 0.169 | 37.4 | 235.3 | 0.194 | 44.1 |
1 CO represents 300 mg of cholesteryl oleate, corresponding to the formulation without PEG. 2 Particle size distribution (PSD), polydispersity index (PdI), and zeta potential (ZP) of all the formulations manufactured.